频域OCT在玻璃体腔注射曲安奈德治疗视网膜静脉阻塞继发黄斑水肿中的临床应用  

Clinical application of IVTA treatment for ME in RVO by Spectra Domain OCT

作　　者：郑利民[1] 罗立琴[1] 杜鹏程[1] 霍建新[1] 杨建华[1] 张琳[1] 王俊琴[1] 

机构地区：[1]包头医学院第一附属医院眼科,内蒙古包头014010

出　　处：《中国医学工程》2012年第6期6-7,9,共3页China Medical Engineering

基　　金：内蒙古自治区高等学校科学研究项目(NJZY11185)

摘　　要：目的通过频域OCT观察玻璃体腔注射曲安奈德(TA)治疗视网膜静脉阻塞继发黄斑水肿的临床疗效。方法回顾性分析38例眼科常规检查及经FFA和频域OCT查均确诊为视网膜静脉阻塞继发黄斑水肿,视力≤0.6,黄斑中心凹厚度(CMT)≥250μm的患者38只眼纳入观察,进行玻璃体腔注射TA(4 mg,0.1 mL)治疗。比较治疗前和治疗后1d及1,2,4,8,12,24周最佳矫正视力(BCVA)改变;治疗前和治疗后1,2,4,8,12,24周的黄斑中心凹厚度(CMT)、黄斑中心容积(CMV)、黄斑区平均厚度(AVG)的改变。结果在治疗后视显提高,术后各时间点(P=0.000)均具有统计学意义,BCVA各点分别为:4周0.4283±0.1657;8周0.6216±0.1527;12周0.6194±0.1893,视力基本持平,24周0.4017±0.1384缓慢下降,术后1周有24例视力提高大于3行。CMT在治疗后明显降低(P=0.000),均具有统计学意义。与基线相比,CMV、AVG两具有显著改变。BCVA分别与CMT、CMV、AVG呈负相关。结论玻璃体腔注射TA治疗视网膜静脉阻塞继发黄斑水肿均可明显改善,减轻黄斑水肿。BCVA分别与CMT、CMV、AVG呈负相关,CMV、AVG也可反映治疗效果。[ Objective ] To observe the efficiency of IVTA for the treatment of ME in RVO by spectra domain OCT. [ Methods ] A total of 38 eyes with ME second to RVO were observed. All patients were diagnosed expecially by FFA and spectra domain OCT, with vision ≤ 0.6 and CMT ≥ 250 μm. All received intravitreal injection of 4mg/0.1mL of TA .BCVA, CMT, CMV, and AVG were compared before and after treatment. [ Results ] After treatment,BCVA were significantly increased in each time point（P=0.000）, BCVA in 4 （BCVA=0.4283 ± 0.1657）, 8 （BCVA=0.6216 ± 0.1527）, 12 （BCVA=0.6194 ± 0.1893） weeks, were similar. After treatment, compared with baseline, the changes of CMT, CMV and AVG were significantly increased in each time point（P=0.000）. [ Conclusion ] IVTA for the treatment of ME in RVO could increase BCVA and reduce ME instinctively. CMT can reveal the effect of treatment better than CMV and AVG.

关 键 词：频域OCT 曲安奈德 视网膜静脉阻塞 黄斑水肿 

分 类 号：R774.5[医药卫生—眼科]